Doyle Mittie
SEC CIK 1918845 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | Chief Medical Off | 52.5K | — | $2.98M | 27 | 2025-12-10 | 2026-08-28 |
Most active insiders at AVTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Sullivan Christopher Ryan | CFO | — | $3.72M |
| 2 | Doyle Mittie | Chief Medical Off | — | $2.98M |
| 3 | VARKI PAUL | CLO | — | $1.51M |
| 4 | Goldman Jonathan | Dir | — | $163.0K |
| 5 | Chan Mitchell | Dir | — | $72.5K |
| 6 | Riley Jennifer | Chief Strategy Off | — | $52.0K |
| 7 | Truex Samantha | Dir | — | — |
| 8 | KANTOFF AARON | Dir | — | — |
| 9 | NEIL GARRY ARTHUR | CEO, Dir | — | — |
| 10 | KAPLAN GILLA | Dir | — | — |
Transactions 27
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-01 16:38 | 2026-08-28 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | M - OptEx | $8.04 | +679 | 52.5K | +1% | +$5,459 |
| DT | 2026-09-01 16:38 | 2026-08-28 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | S - Sale+OE | $20.00 | -679 | 51.8K | -1% | -$13.6K |
| DT | 2026-08-19 16:10 | 2026-08-17 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | M - OptEx | $12.65 | +1,000 | 52.8K | +2% | +$12.7K |
| DT | 2026-08-19 16:10 | 2026-08-17 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | S - Sale+OE | $20.00 | -1,000 | 51.8K | -2% | -$20.0K |
| DT | 2026-08-12 16:10 | 2026-08-10 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | M - OptEx | $8.04 | +679 | 52.5K | +1% | +$5,459 |
| DT | 2026-08-12 16:10 | 2026-08-10 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | S - Sale+OE | $20.00 | -679 | 51.8K | -1% | -$13.6K |
| DT | 2026-07-29 16:05 | 2026-07-27 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | M - OptEx | $12.65 | +1,000 | 52.8K | +2% | +$12.7K |
| DT | 2026-07-29 16:05 | 2026-07-27 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | S - Sale+OE | $20.00 | -1,000 | 51.8K | -2% | -$20.0K |
| DMT | 2026-07-02 16:05 | 2026-06-30 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | M - OptEx | $10.89 | +4,654 | 56.4K | +9% | +$50.7K |
| DT | 2026-07-02 16:05 | 2026-06-30 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | S - Sale+OE | $20.00 | -4,654 | 51.8K | -8% | -$93.1K |
| DT | 2026-06-25 17:24 | 2026-06-23 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | M - OptEx | $8.04 | +1,450 | 53.2K | +3% | +$11.7K |
| DT | 2026-06-25 17:24 | 2026-06-23 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | S - Sale+OE | $18.00 | -1,450 | 51.8K | -3% | -$26.1K |
| 2026-06-12 16:26 | 2026-06-10 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | F - Tax | $13.10 | -1,084 | 51.8K | -2% | -$14.2K | |
| DT | 2026-06-01 16:05 | 2026-05-28 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | M - OptEx | $8.04 | +679 | 47.8K | +1% | +$5,459 |
| DT | 2026-06-01 16:05 | 2026-05-28 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | S - Sale+OE | $16.00 | -679 | 47.1K | -1% | -$10.9K |
| 2026-05-26 16:10 | 2026-05-21 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | A - Grant | $0.00 | +43.5K | 47.1K | +1,201% | $0 | |
| DT | 2026-05-19 16:10 | 2026-05-15 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | M - OptEx | $12.65 | +3,000 | 6,622 | +83% | +$38.0K |
| DT | 2026-05-19 16:10 | 2026-05-15 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | S - Sale+OE | $18.76 | -3,000 | 3,622 | -45% | -$56.3K |
| DMT | 2026-05-07 16:16 | 2026-05-05+ | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | M - OptEx | $11.40 | +108.2K | 110.2K | +5,570% | +$1.23M |
| DMT | 2026-05-07 16:16 | 2026-05-05+ | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | S - Sale+OE | $20.61 | -108.2K | 3,622 | -97% | -$2.23M |
| DT | 2026-04-08 16:51 | 2026-04-06 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | M - OptEx | $12.65 | +3,970 | 7,592 | +110% | +$50.2K |
| DT | 2026-04-08 16:51 | 2026-04-06 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | S - Sale+OE | $18.01 | -3,970 | 3,622 | -52% | -$71.5K |
| DT | 2026-04-03 15:13 | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | M - OptEx | $8.04 | +679 | 4,301 | +19% | +$5,459 |
| DT | 2026-04-03 15:13 | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | S - Sale+OE | $16.00 | -679 | 3,622 | -16% | -$10.9K |
| DM | 2026-03-18 | 2026-03-16 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | M - OptEx | $11.57 | +25.5K | 29.1K | +704% | +$294.9K |
| D | 2026-03-18 | 2026-03-16 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | S - Sale+OE | $16.15 | -25.5K | 3,622 | -88% | -$411.7K |
| 2025-12-12 | 2025-12-10 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Off | F - Tax | $4.10 | -1,013 | 3,622 | -22% | -$4,153 |
Purchase Sale Sale after option exercise All abbreviations